Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESTO: AZD6793 in Moderate to Very Severe COPD
NCT07082738Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 2, randomised, double-blind trial of AZD6793 in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Annualised rate of moderate or severe COPD exacerbations at 24 weeks. Started Jun 2025; status: recruiting.
02
Drugs
AZD6793
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07082738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07082738.